Navigation Links
Atacama Labs Enters Into Partnership With Excella Gmbh, Which is Part of Fareva Holding, a Top 10 Global Contract Manufacturer

HELSINKI, Finland, March 4, 2010 /PRNewswire/ --

- A Finnish Company ATACAMA LABS OY and a German Based EXCELLA GmbH (Fareva Holding SA) Have Signed a Contract Manufacturing Agreement to Jointly Market and Sell PDG Granule and Tablet Manufacturing Services for the Pharmaceutical Industry

- Excella / Atacama Labs Offer for the Pharmaceutical Industry

Atacama Labs Oy has developed an innovative oral drug delivery technology (called 'pneumatic dry granulation' or 'PDG Technology(TM)'). The technology is aimed to replace existing solid dosage form development and manufacturing methods (like wet granulation or standard roller compaction) and will help both NCE galenic developers and life cycle managers to overcome development or differentiation issues.

The Excella / Atacama Labs partnership offers a cGMP compliant and FDA / EMEA / Anvisa certified environment to house Atacama's innovative and fully automated PDG equipment.

"We can develop almost any API (including difficult ones) into higher drug load tablets with good hardness and dissolution profiles and our clients can profit from new tablet characteristics to extend the life cycle of expiring drugs, which can mean several more years of protected sales of a blockbuster drug. In both cases, global economics can be hundreds of millions of additional revenue, naturally subject to magnitude of drug revenue," Mr. Mittwich, CEO of the Atacama Labs Oy concludes.

Fareva Holding SA : Manufacturing excellence

Excella GmbH is part of FAREVA Holding, one of the top 10 contract manufacturing organizations in the world. Fareva today is covering services in four fields - Pharmaceuticals, Cosmetics, Home Care & Industrial and Food.

FAREVA's Pharma Division provides a full service, ranging from pharmaceutical and chemical development, pilot scale manufacturing, supply of clinical studies till industrial-scale production, packaging and quality control. Ten pharmaceutical sites located throughout Europe serve the customer's needs for practically all marketed dosage forms as well as APIs.

Excella GmbH - located in Nuremberg, Germany - provides Contract Manufacturing Services, especially for the development, clinical supply and commercial manufacturing of solid dosage forms specially for cytotoxics, high potent or other critical actives with low occupational exposure levels.

"Atacama Lab's Pneumatic Dry Granulation or PDG Technology(TM) is revolutionary in the sense that it offers significant advantages in terms of API treatability, development speed and costs over today's dry and wet granulation processes " Dr. Michael Tschope , General Manager Pharma, Excella GmbH.

About Atacama Labs Oy

Atacama Labs Oy is a privately owned specialty pharmaceutical company that offers

    - galenic development from test granulations to full galenic development,
    - contract manufacturing services from tablets to fully packaged

    The Company is located in Helsinki, Finland.

SOURCE Atacama Labs Oy

Back to top
SOURCE Atacama Labs Oy
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Fibrocell Science, Inc. Enters Into Financing Agreement
2. US Fermenters Market to Reach $180 million by 2015, According to New Report by Global Industry Analysts, Inc.
3. Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
4. The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close
5. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
6. MRI & X-Ray Outsourcing Increasing From Hospitals and Imaging Centers Worldwide
7. iLife Americas, LLC Enters U.S. Wellness and Therapeutic Markets
8. China Biologic Products Enters into a Strategic Research and Development Agreement with IBT of CAMS
9. Childrens Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma
10. Pieris AG Enters into Anticalin Collaboration With Allergan, Inc.
11. Dr M Group Selects Health Robotics Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia
Post Your Comments:
(Date:12/1/2015)... 1, 2015 Frost & Sullivan is ... program addresses ways companies can innovate and transform ... --> ... --> ... well as the disrupting factors altering the industry, ...
(Date:12/1/2015)... , Dec. 1, 2015  CardioCell LLC, a ... stem cells for cardiovascular indications, intends to proceed ... based on recommendations from a Heart Failure Advisory ... Scientific Advisory Board members . In a ... Phase IIa safety and efficacy data from CardioCell,s ...
(Date:12/1/2015)...  Symic, a clinical-stage biotherapeutics company developing multiple compounds ... announced that it has secured $25 million in a ... its lead candidates SB-030 and SB-061. The financing was ... all existing major investors, as well as several new ... by Symic to over $43 million since being founded ...
(Date:12/1/2015)... ... December 01, 2015 , ... Matthew “Tex” VerMilyea, PhD, HCLD, has joined Texas ... oversee all IVF lab procedures as well as continue his research efforts into the ... miles to Auckland, New Zealand to bring home a High Complexity Clinical Laboratory Director ...
Breaking Biology Technology:
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Sensors - Technology and Patent Infringement Risk Analysis" ... --> Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
(Date:11/18/2015)... new scientific discoveries deepen our understanding of how cancer ... challenges in better using that knowledge to guide treatment ... children continue to survive pediatric cancer, that counseling may ... John M. Maris, M.D ., a pediatric oncologist ... --> John M. Maris, M.D ., ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
Breaking Biology News(10 mins):